Combining new cancer drugs to treat resistant ovarian cancer

Who could benefit from this research

What this research studies

This research investigates the use of a new drug, cirtuvivint, in combination with an existing treatment, olaparib, for patients with platinum-resistant ovarian cancer. The study focuses on patients who have specific genetic mutations (BRCA1/2) or deficiencies in DNA repair mechanisms. By exploring how these drugs work together, the research aims to overcome resistance to current therapies and improve treatment outcomes. Patients may be monitored for changes in tumor response and overall health as part of the treatment process.

Why it matters

Where this research is happening

• University of Colorado Denver
  Aurora, United States Active

Researchers

• Principal investigator: Corr, Bradley — University of Colorado Denver
• Study coordinator: Corr, Bradley

Related research

Other NIH-funded projects on the same topics.

• Mitotic MTH1 Inhibitors for Platinum-Resistant Ovarian Cancer

  A treatment approach targeting a specific cancer cell weakness (MTH1) to help women whose ovarian cancer stopped responding to platinum-based therapy.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11421329

• Cirtuvivint plus PARP inhibitor in BRCA/HRD ovarian cancer

  A new treatment approach combines a CLK/DYRK inhibitor with a PARP inhibitor to help women with BRCA mutations or HRD ovarian cancer who have become resistant to platinum therapy.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11398114

• Targeting cancer-specific protein variants to guide T-cell therapy in platinum-resistant ovarian cancer

  Aims to find unique protein variants in platinum-resistant ovarian cancer to guide T-cell receptor therapy for patients.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11332288

• Why some ovarian cancers resist platinum chemotherapy: changes in tumor metabolism

  This project looks at how ovarian tumors change their metabolism when they stop responding to platinum chemotherapy and seeks new targets and markers to help women with recurrent high-grade serous ovarian cancer.

  NIH research Jesse Brown VA Medical Center · Chicago, United States · NIH-11212826

• Cirtuvivint plus olaparib for BRCA/HRD ovarian cancer that stopped responding to platinum

  This work adds cirtuvivint to the PARP drug olaparib to try to help people with BRCA-mutated or homologous recombination–deficient ovarian cancer that no longer responds to platinum chemotherapy.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11179129

• Finding new treatments for platinum-resistant ovarian cancer using T-cell therapy

  This study is looking for new ways to help patients with tough-to-treat ovarian cancer by analyzing their tumor samples to find specific targets that can be attacked by the immune system, which could lead to better treatments for them.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11115806

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.